Cyclarity Therapeutics

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
7-ketocholesterol / oxysterols accumulated in macrophage-derived foam cellsSmall molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 May 2026Topline resultUDP-003Phase 1 results: primary, secondary and exploratory endpoints met
Cyclarity Therapeutics, Inc. · Source ↗

Financial reports

No financial reports recorded.